Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

被引：18

作者：

George, Daniel J. ^{[1
]}

Hessel, Colin ^{[2
]}

Halabi, Susan ^{[3
,4
]}

Michaelson, M. Dror ^{[5
]}

Hahn, Olwen ^{[6
]}

Walsh, Meghara ^{[7
]}

Picus, Joel ^{[8
]}

Small, Eric J. ^{[9
]}

Dakhil, Shaker ^{[10
]}

Feldman, Darren R. ^{[11
]}

Mangeshkar, Milan ^{[2
]}

Scheffold, Christian ^{[2
]}

Morris, Michael J. ^{[11
]}

Choueiri, Toni K. ^{[7
]}

机构：

[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[2] Exelixis Inc, Alameda, CA USA

[3] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA

[4] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[6] Alliance Protocol Operat Off, Chicago, IL USA

[7] Dana Farber Partners CancerCare, Boston, MA USA

[8] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[9] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Univ Kansas Wichita, Wichita, KS USA

[11] Memorial Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2019年 / 24卷 / 11期

关键词：

THERAPY;

D O I：

10.1634/theoncologist.2019-0316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

引用

页码：1497 / 1501

页数：5

共 8 条

[1] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Choueiri, Toni K.
Hessel, Colin
Halabi, Susan
Sanford, Ben
Michaelson, M. Dror
Hahn, Olwen
Walsh, Meghara
Olencki, Thomas
Picus, Joel
Small, Eric J.
Dakhil, Shaker
Feldman, Darren R.
Mangeshkar, Milan
Scheffold, Christian
George, Daniel
Morris, Michael J.
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 94 : 115 - 125
[2] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Choueiri, Toni K.
Halabi, Susan
Sanford, Ben L.
Hahn, Olwen
Michaelson, M. Dror
Walsh, Meghara K.
Feldman, Darren R.
Olencki, Thomas
Picus, Joel
Small, Eric J.
Dakhil, Shaker
George, Daniel J.
Morris, Michael J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 591 - +
[3] Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, Toni K.
Motzer, Robert J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) : 354 - 366
[4] Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma
McKay, Rana R.
Bosse, Dominick
Choueiri, Toni K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (36) : 3615 - +
[5] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J.
Tannir, N. M.
McDermott, D. F.
Frontera, O. Aren
Melichar, B.
Choueiri, T. K.
Plimack, Elizabeth R.
Barthelemy, P.
Porta, C.
George, S.
Powles, T.
Donskov, F.
Neiman, V.
Kollmannsberger, C. K.
Salman, P.
Gurney, H.
Hawkins, R.
Ravaud, A.
Grimm, M. -O.
Bracarda, S.
Barrios, C. H.
Tomita, Y.
Castellano, D.
Rini, B. I.
Chen, A. C.
Mekan, S.
McHenry, M. B.
Wind-Rotolo, M.
Doan, J.
Sharma, P.
Hammers, H. J.
Escudier, B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) : 1277 - 1290
[6] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, Robert J.
Penkov, Konstantin
Haanen, John
Rini, Brian
Albiges, Laurence
Campbell, Matthew T.
Venugopal, Balaji
Kollmannsberger, Christian
Negrier, Sylvie
Uemura, Motohide
Lee, Jae L.
Vasiliev, Aleksandr
Miller, Wilson H., Jr.
Gurney, Howard
Schmidinger, Manuela
Larkin, James
Atkins, Michael B.
Bedke, Jens
Alekseev, Boris
Wang, Jing
Mariani, Mariangela
Robbins, Paul B.
Chudnovsky, Aleksander
Fowst, Camilla
Hariharan, Subramanian
Huang, Bo
di Pietro, Alessandra
Choueiri, Toni K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) : 1103 - 1115
[7] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Hawkins, Robert
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio J.
Borchiellini, Delphine
Szczylik, Cezary
Markus, Maurice
McDermott, Raymond S.
Bedke, Jens
Tartas, Sophie
Chang, Yen-Hwa
Tamada, Satoshi
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Powles, Thomas
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) : 1116 - 1127
[8] Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Yakes, F. Michael
Chen, Jason
Tan, Jenny
Yamaguchi, Kyoko
Shi, Yongchang
Yu, Peiwen
Qian, Fawn
Chu, Felix
Bentzien, Frauke
Cancilla, Belinda
Orf, Jessica
You, Andrew
Laird, A. Douglas
Engst, Stefan
Lee, Lillian
Lesch, Justin
Chou, Yu-Chien
Joly, Alison H.
[J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2298 - 2308

← 1 →